Elysium Health has secured $40.0 million in new funding from investors. The company focuses on translating scientific advancements into health products designed to help people live healthier for longer. Elysium Health collaborates with scientists and clinicians globally, emphasizing research, preclinical studies, and human clinical trials to develop innovative health solutions, particularly compounds found in nature.
Its mission is to solve significant health challenges through science, guided by a Scientific Advisory Board that includes Nobel Prize winners and experts across various scientific disciplines. Elysium Health's first product, Basis, is a proprietary formulation designed to support long-term cellular health. Basis is clinically proven to increase NAD+ levels, which are crucial for energy creation, regulating circadian rhythms, and maintaining healthy DNA.
This capital infusion marks a significant milestone for Elysium Health, underscoring investor confidence in its scientific approach and product development pipeline. The company plans to deploy the funds to accelerate its research and development efforts, expand its product portfolio, and scale its operational capabilities to reach a broader audience. The investment will support Elysium Health's continued commitment to rigorous scientific validation and the translation of cutting-edge research into accessible health products.
Looking ahead, Elysium Health aims to further solidify its position in the health and wellness sector by continuing to develop science-backed solutions that proactively support human health and longevity.
